| Promore Pharma AB (publ) Interim report January – September 2018 | Report (pdf) |
| Interim report January – June 2018 | Report (pdf) |
| Promore Pharma AB (publ) Interim report January – March 2018 | Report (pdf) |
| Year-end report 2017 | Report (pdf) |
The RespiraSense™ business model consists of several components that together create a complete delivery that generates attractive gross margins and recurring revenues.
To avoid preventable respiratory failure events by transforming the standard of care in patient monitoring.
To become the de facto standard-of-care for monitoring respiratory compromised patients in Europe and the US.